Stephanie Gaillard (Stéphanie Gaillard)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Combination Therapy

Advanced Cancer

Dna Damage Response

Top Venues

Cancer research

JCO precision oncology

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Jayaprakash Mandal, Tiffany Nicole Jones, Juliane Marie Liberto, Stephanie Gaillard, Tian-Li Wang, Ie-Ming Shih
Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication. Cancer research (2024)
Jayaprakash Mandal, Tiffany Nicole Jones, Juliane Marie Liberto, Stephanie Gaillard, Tian-Li Wang, Ie-Ming Shih
Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication. Cancer research (2024)
Joyce F Liu, Stephanie Gaillard, Andrea E Wahner Hendrickson, Oladapo O Yeku, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang, Natalie Compton, Amanda Baines, Emeline Bacqué, Xiaohong Liu, Brunella Felicetti, Gottfried E Konecny
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO precision oncology 8 (2024)
Joyce F Liu, Stephanie Gaillard, Andrea E Wahner Hendrickson, Oladapo O Yeku, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang, Natalie Compton, Amanda Baines, Emeline Bacqué, Xiaohong Liu, Brunella Felicetti, Gottfried E Konecny
Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO precision oncology 8 (2024)
Zheng-Cheng Yu, Tianhe Li, Ellen Tully, Peng Huang, Chih-Ning Chen, Philipp Oberdoerffer, Stephanie Gaillard, Ie-Ming Shih, Tian-Li Wang
Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors. Cancer research (2023)
Channing J Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N Durham, Nilofer S Azad, Daniel A Laheru, Ilene Browner, Sushant K Kachhap, Kavya Boyapati, Thomas A Odeny, Deborah K Armstrong, Christian F Meyer, Stephanie Gaillard, Julie R Brahmer, Ivelisse Page, Hao Wang, Luis A Diaz
Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer research communications 3 (2) (2023)
Stephanie L Wethington, Payal Deepak Shah, Lainie P Martin, Janos L Tanyi, Nawar A Latif, Mark A Morgan, Drew A Torigian, Diego Rodriguez, Simon A Smith, Emma Dean, Susan M Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J Brown, Wei-Ting Hwang, Deborah K Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) trial in acquired PARP-inhibitor-resistant homologous recombination deficient ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Channing J Paller, Lin Wang, Wei Fu, Rajendra Kumar, Jennifer N Durham, Nilofer S Azad, Daniel A Laheru, Ilene Browner, Sushant K Kachhap, Kavya Boyapati, Thomas A Odeny, Deborah K Armstrong, Christian F Meyer, Stephanie Gaillard, Julie R Brahmer, Ivelisse Page, Hao Wang, Luis A Diaz
Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer research communications 3 (2) (2023)
Yao-An Shen, Jiaxin Hong, Ryoichi Asaka, Fang-Chi Hsu, Yohan Suryo Rahmanto, Jin-Gyoung Jung, Yu-Wei Chen, Ting-Tai Yen, Alicja Tomaszewski, Cissy Zhang, Nabeel Attarwala, Angelo M DeMarzo, Ben Davidson, Chi-Mu Chuang, Xi Chen, Stephanie Gaillard, Anne Le, Ie-Ming Shih, Tian-Li Wang
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer research 80 (20) (2020)
Youngran Park, Michael Herman Chui, Yohan Suryo Rahmanto, Zheng-Cheng Yu, Raghavendra A Shamanna, Marina A Bellani, Stephanie Gaillard, Ayse Ayhan, Akila Viswanathan, Michael M Seidman, Sonia Franco, Anthony K L Leung, Vilhelm A Bohr, Ie-Ming Shih, Tian-Li Wang
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (18) (2019)